CNBCLean R·
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Read at CNBC →
Business · 1 sources covering this
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/bab14711a16a87fab877112977b289cc216acb29" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update"></iframe>
